TAGAMET HB 200
LOE ApproachingNDAORALSUSPENSION
Approved
Jul 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TAGAMET HB 200 is a small-molecule oral suspension approved in 1999 for over-the-counter use. The drug belongs to the H2-receptor antagonist class, commonly used for heartburn and acid reflux relief. It represents a mature, well-established product in the gastrointestinal therapeutic area.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), indicating consolidation and cost-focus rather than growth-oriented team expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TAGAMET HB 200 offers limited career growth opportunities given the LOE-approaching lifecycle and minimal linked job openings. This role suits professionals seeking stabilization in a mature portfolio with focus on cost management, compliance, and operational efficiency rather than innovation.
Brand ManagerProduct Manager
Worked on TAGAMET HB 200 at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.